These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 7742595)
1. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595 [TBL] [Abstract][Full Text] [Related]
2. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508 [TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609 [TBL] [Abstract][Full Text] [Related]
4. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy. Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760 [TBL] [Abstract][Full Text] [Related]
5. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611 [TBL] [Abstract][Full Text] [Related]
6. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression. Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184 [TBL] [Abstract][Full Text] [Related]
10. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Looi LM; Cheah PL Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259 [TBL] [Abstract][Full Text] [Related]
11. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229 [TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Foekens JA; Portengen H; van Putten WL; Trapman AM; Reubi JC; Alexieva-Figusch J; Klijn JG Cancer Res; 1989 Dec; 49(24 Pt 1):7002-9. PubMed ID: 2555057 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. Ray A; Sharma BK; Kaur S; Sharma S; Sharma JK Indian J Exp Biol; 2004 Mar; 42(3):253-8. PubMed ID: 15233293 [TBL] [Abstract][Full Text] [Related]
15. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Thor AD; Edgerton SM; Liu S; Moore DH; Kwiatkowski DJ Clin Cancer Res; 2001 Aug; 7(8):2415-24. PubMed ID: 11489821 [TBL] [Abstract][Full Text] [Related]
16. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641 [TBL] [Abstract][Full Text] [Related]
17. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907 [TBL] [Abstract][Full Text] [Related]
18. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study. Martinazzi M; Crivelli F; Zampatti C; Martinazzi S Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712 [TBL] [Abstract][Full Text] [Related]
19. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix. Ray A; Naik SL; Sharma BK Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217 [TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay. Narita T; Funahashi H; Satoh Y; Imai T; Takagi H Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]